Advocacy intelligence hub — real-time data for patient organizations
Beijing Immupeutics Medicine Technology Limited — PHASE1
Tianjin Medical University Cancer Institute and Hospital — PHASE2
MediLink Therapeutics (Suzhou) Co., Ltd. — PHASE3
Changhai Hospital — PHASE2
The First Affiliated Hospital of Zhengzhou University — PHASE3
Shanghai Junshi Bioscience Co., Ltd. — PHASE2
CSPC Megalith Biopharmaceutical Co.,Ltd. — PHASE3
Tianjin Medical University Cancer Institute and Hospital — PHASE2
Fudan University — PHASE2
Jonsson Comprehensive Cancer Center — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Yervoy
Bristol-Myers Squibb Company
CYRAMZA
(ramucirumab)Orphan drugstandardEli Lilly and Company
Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]
12.1 Mechanism of Action Ramucirumab is a VEGFR2 antagonist that specifically binds VEGFR2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VE...
Tevimbra
(tislelizumab-jsgr)Orphan drugstandardBeOne Medicines USA, Inc.
Programmed Death Receptor-1 Blocking Antibody [EPC]
12.1 Mechanism of Action Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokin...
Lijie Tan, MD
Shanghai Zhongshan Hospital
Xiaodong Zhang
Peking University Cancer Hospital & Institute
Hui Liu, Professor
Sun yat-sen universtiy cancer center
Jinming Yu, Dr.
Shandong Cancer Hospital and Institute
Lin Shen
Peking University Cancer Hospital & Institute
Feng Wang, Doctor
Wuxi city people's hospital
View all Squamous cell carcinoma of the esophagus specialists →